{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:26:43Z","timestamp":1787030803970,"version":"build-2736575974"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Metastatic breast cancer (MBC) has traditionally been managed as an incurable systemic disease in which the main goals are survival extension, symptom control, and preservation of quality of life. This principle remains appropriate for most patients. However, contemporary systemic therapies, high-resolution imaging, antibody-drug conjugates (ADCs), immune checkpoint inhibition, liquid biopsy, and metastasis-directed therapy (MDT) have made prolonged no evidence of disease (NED) clinically recognizable in selected patients. This Hypothesis and Theory article proposes NED-oriented oncology as a testable framework for carefully selected patients with MBC. The central premise is that complete response and NED should be separated conceptually: complete response is a radiological treatment-response category, whereas NED is a clinical state produced by the integration of systemic disease control, biological remodeling of the tumor immune microenvironment (TIME), and local eradication of all residual visible lesions. We propose a Clinical NED Score to structure candidate selection, a TIME-modifiability layer to estimate biological convertibility, and a five-step algorithm in which systemic therapy is used to generate deep response and immune-ecological remodeling before MDT is considered at maximal response. ADCs are discussed as potential tumor-ecosystem engineering tools because their effects may extend beyond direct cytotoxicity to bystander killing, immunogenic cell death, antigen release, and immune reconfiguration. This framework does not imply that MBC is broadly curable. Rather, it argues that durable NED is a clinically meaningful, prospectively testable state that should be distinguished from transient radiological response and evaluated using endpoints such as NED interval, polymetastatic progression-free survival, systemic therapy switch-free survival, ctDNA-negative duration, and quality-of-life preservation.<\/jats:p>","DOI":"10.3389\/fonc.2026.1895475","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:28:39Z","timestamp":1787027319000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["NED-oriented oncology in metastatic breast cancer: a hypothesis-driven framework integrating the tumor immune microenvironment, antibody-drug conjugates, and metastasis-directed therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Shinichiro","family":"Kashiwagi","sequence":"first","affiliation":[{"name":"Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.25881","article-title":"Analysis of breast cancer mortality in the US--1975 to 2019","volume":"331","author":"Caswell-Jin","year":"2024","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: end-of-study analysis of CLEOPATRA","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355)","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01676-4","article-title":"No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer","volume":"126","author":"Veitch","year":"2022","journal-title":"Br J Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41523-024-00713-8","article-title":"Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer","volume":"10","author":"Cucciniello","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.cell.2018.08.039","article-title":"A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging","volume":"174","author":"Keren","year":"2018","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1876-x","article-title":"The single-cell pathology landscape of breast cancer","volume":"578","author":"Jackson","year":"2020","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00911-1","article-title":"A single-cell and spatially resolved atlas of human breast cancers","volume":"53","author":"Wu","year":"2021","journal-title":"Nat Genet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0026-6","article-title":"Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer","volume":"1","author":"Ali","year":"2020","journal-title":"Nat Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00286-3","article-title":"Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups","volume":"24","author":"Pasquier","year":"2023","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01857-3","article-title":"Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (CURB oligoprogression): an open-label, randomised, controlled, phase 2 study","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.08.036","article-title":"Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study","volume":"83","author":"Milano","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2017.08.032","article-title":"Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial","volume":"126","author":"Trovo","year":"2018","journal-title":"Radiother Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer","volume":"25","author":"Loi","year":"2014","journal-title":"Ann Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials","volume":"32","author":"Adams","year":"2014","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0078-7","article-title":"Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis","volume":"24","author":"Savas","year":"2018","journal-title":"Nat Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01323-8","article-title":"A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer","volume":"27","author":"Bassez","year":"2021","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment for effective immunotherapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B49","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence","volume":"25","author":"Coombes","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30444-7","article-title":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial","volume":"21","author":"Turner","year":"2020","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B55","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","article-title":"Antibody-drug conjugates for cancer treatment","volume":"69","author":"Lambert","year":"2018","journal-title":"Annu Rev Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/antib2010113","article-title":"Antibody drug conjugates as cancer therapeutics","volume":"2","author":"Trail","year":"2013","journal-title":"Antibodies"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920915980","article-title":"Novel antibody-drug conjugates for triple negative breast cancer","volume":"12","author":"Nagayama","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-HER2 antibody-drug conjugate, in tumors with HER2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3546","article-title":"Antibody-maytansinoid conjugates designed to bypass multidrug resistance","volume":"70","author":"Kovtun","year":"2010","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00118","article-title":"Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting Trop-2 linked to SN-38, in ovarian cancer","volume":"10","author":"Perrone","year":"2020","journal-title":"Front Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.09.009","article-title":"Informing the tolerability of cancer treatments using patient-reported outcome measures: summary of an FDA and Critical Path Institute workshop","volume":"21","author":"Kluetz","year":"2018","journal-title":"Value Health"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1895475\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:28:40Z","timestamp":1787027320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1895475\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":68,"alternative-id":["10.3389\/fonc.2026.1895475"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1895475","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1895475"}}